In case you missed it, last week we covered the basics of clinical research but there is a lot more to how a drug eventually makes it to patients. In fact, only 12 percent of medicines that enter clinical research will ever make it to patients.¹

Whether it is discovering a therapy that could work for an individual patient faster or finding new ways to treat the root cause of a disease, at UCB, we are committed to continuing to unlock the science to improve the lives of patients.

At UCB, we strive to discover and deliver new solutions patients value. Whether it’s through leveraging big data, thinking outside the box to overcome barriers, or collaborating with others in the healthcare industry—initiatives across UCB are at the forefront of research, and recently, our experts have been in the news talking about what we’re working on.

UCB is pleased to announce 32 recipients were awarded the 2018 UCB Family Epilepsy Scholarship. This year’s winners are beginning their academic year at 31 schools across the country where awards will support their undergraduate or graduate education. Hailing from 17 states, this diverse group of passionate advocates includes people living with epilepsy or caregiving for someone living with epilepsy, including parents and siblings.

As one of the first winners of the UCB Family Epilepsy Scholarship, Maria reflects on the goals, choices, and experiences that have shaped her ever-evolving career in science.

As part of Psoriasis Action Month, Alisha Bridges, an award-winning writer and community advocate, recently shared her story about living with psoriasis.

UCB supports local events across the country that benefit patients. Recently, our employees participated in two different runs in support of the epilepsy and Crohn’s disease communities.

FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters

An estimated 3.3 million individuals in the U.S. are living with spondyloarthritis^1,2 (SpA), an inflammatory disease affecting the spine, and in some people, the joints of the arms and legs, skin, intestines, and eyes. An underdiagnosed condition, most people with SpA first experience symptoms in their 20s or 30s but typically wait as many as 10 years between symptom onset and SpA diagnosis. * 

August is Psoriasis Awareness Month so we’re shining a spotlight on the disease and how UCB is working to deliver solutions that patients value.